Dr. Charles Ryan Discusses IMAAGEN Trial Update for Prostate Cancer

Video

Charles J. Ryan, MD, professor of Clinical Medicine, Urology, Helen Diller Family Comprehensive Cancer Center at the University of California, San Francisco, provides an update to the IMAAGEN trial, which explored the effects of abiraterone acetate (Zytiga) and low-dose prednisone on prostate-specific antigen and radiographic disease progression in patients with nonmetastatic castration-resistant prostate cancer

Charles J. Ryan, MD, professor of Clinical Medicine, Urology, Helen Diller Family Comprehensive Cancer Center at the University of California, San Francisco, provides an update to the IMAAGEN trial, which explored the effects of abiraterone acetate (Zytiga) and low-dose prednisone on prostate-specific antigen (PSA) and radiographic disease progression in patients with nonmetastatic castration-resistant prostate cancer (CRPC).

The phase II study is examining an important patient population, as there is no standard of care for them, Ryan explains, and most patients progress to metastatic disease.

The findings show that the addition of 5 mg of prednisone was not associated with significant adverse events, he says. Additionally, there was a high PSA response proportion of 90%, the time to PSA progression was 28 months, and the time to metastatic progression has not been determined.

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD
Ruben Olivares, MD
Phillip J. Koo, MD